Sirtuins (SIRTs) are nicotine adenine dinucleotide (+)-dependent histone deacetylases
regulating critical signaling pathways in prokaryotes and eukaryotes, and are involved in …

Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

Background An unmet need exists for focal segmental glomerulosclerosis (FSGS) treatment.
In an 8-week, phase 2 trial, sparsentan, a dual endothelin–angiotensin receptor antagonist …

Chronic kidney disease (CKD) is estimated to affect 10–14% of global population. Kidney
fibrosis, characterized by excessive extracellular matrix deposition leading to scarring, is a …

Background Sparsentan is a novel, non-immunosuppressive, single-molecule, dual
endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial …

Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …

Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Chronic kidney disease (CKD) is a devastating condition that is reaching epidemic levels
owing to the increasing prevalence of diabetes mellitus, hypertension and obesity, as well …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Background Resistant hypertension is associated with increased cardiovascular risk. The
endothelin pathway has been implicated in the pathogenesis of hypertension, but it is …